These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36128575)

  • 1. Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights.
    Cammarota A; Zanuso V; Pressiani T; Personeni N; Rimassa L
    J Hepatocell Carcinoma; 2022; 9():1011-1027. PubMed ID: 36128575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints.
    Giuffrida P; Celsa C; Antonucci M; Peri M; Grassini MV; Rancatore G; Giacchetto CM; Cannella R; Incorvaia L; Corsini LR; Morana P; La Mantia C; Badalamenti G; Brancatelli G; Cammà C; Cabibbo G
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
    Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Vogel A; Tovoli F; Ueshima K; Aikata H; López CL; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Tamai T; Saito K; Dutcus CE; Lencioni R
    J Hepatol; 2023 Jan; 78(1):133-141. PubMed ID: 36341767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RECIST 1.1, mRECIST, and Choi criteria for evaluating treatment response and survival outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab.
    Kim DH; Min EJ; Kim B; Choi JY; Jang JW; Sung PS; Han JW; Kim H; Choi JI
    Eur Radiol; 2024 Jul; ():. PubMed ID: 39080067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
    Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
    Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRECIST for HCC: Performance and novel refinements.
    Llovet JM; Lencioni R
    J Hepatol; 2020 Feb; 72(2):288-306. PubMed ID: 31954493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
    Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
    Cabibbo G; Celsa C; Enea M; Battaglia S; Rizzo GEM; Busacca A; Matranga D; Attanasio M; Reig M; Craxì A; Cammà C
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.
    Xu Y; Yang Y; Ouyang J; Zhou Y; Li L; Ye F; Yang H; Huang Z; Zhou A; Zhang W; Zhou J; Zhao X; Zhao H
    Eur Radiol; 2024 Apr; 34(4):2244-2255. PubMed ID: 37740779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
    Lencioni R; Montal R; Torres F; Park JW; Decaens T; Raoul JL; Kudo M; Chang C; Ríos J; Boige V; Assenat E; Kang YK; Lim HY; Walters I; Llovet JM
    J Hepatol; 2017 Jun; 66(6):1166-1172. PubMed ID: 28131794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies.
    Kudo M; Montal R; Finn RS; Castet F; Ueshima K; Nishida N; Haber PK; Hu Y; Chiba Y; Schwartz M; Meyer T; Lencioni R; Llovet JM
    Clin Cancer Res; 2022 Aug; 28(16):3443-3451. PubMed ID: 34907081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
    Personeni N; Bozzarelli S; Pressiani T; Rimassa L; Tronconi MC; Sclafani F; Carnaghi C; Pedicini V; Giordano L; Santoro A
    J Hepatol; 2012 Jul; 57(1):101-7. PubMed ID: 22414760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma.
    Raoul JL; Park JW; Kang YK; Finn RS; Kim JS; Yeo W; Polite BN; Chao Y; Walters I; Baudelet C; Lencioni R
    Liver Cancer; 2014 Oct; 3(3-4):439-50. PubMed ID: 26280005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria.
    Zhou M; Zhang C; Nie J; Sun Y; Xu Y; Wu F; Huang Y; Li S; Wang Y; Zhou Y; Zheng T
    Front Oncol; 2021; 11():764189. PubMed ID: 34956885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
    Yu H; Bai Y; Xie X; Feng Y; Yang Y; Zhu Q
    BMJ Open; 2022 Jun; 12(6):e052294. PubMed ID: 35649603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
    Wang R; Lin N; Mao B; Wu Q
    J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M; Bouattour M; Wassermann J; Bruno O; Dreyer C; Larroque B; Castera L; Vilgrain V; Belghiti J; Raymond E; Faivre S
    Oncologist; 2014 Apr; 19(4):394-402. PubMed ID: 24652387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
    Cammarota A; Zanuso V; Manfredi GF; Murphy R; Pinato DJ; Rimassa L
    Ther Adv Med Oncol; 2023; 15():17588359221148029. PubMed ID: 36643654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.